Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program
- Person
- Jørn Skibsted Jakobsen, MD, PhD
- Title
- Chief Development Officer, Urology & Uro-Oncology
- Action
- appointed
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The appointment signals commitment to advancing NDV-01, potentially reducing execution risk ahead of the Phase 3 SPECTRUM trial.
Market read
Exec hire is a modest catalyst for RLMD; limited immediate trading impact but relevant for longer‑term pipeline outlook.
What to watch
Execution risk of Phase 3 remains high; leadership change does not guarantee trial success.
Background
Relmada Therapeutics (NASDAQ:RLMD) is a clinical‑stage biotech developing NDV-01 for non‑muscle invasive bladder cancer and sepranolone for CNS disorders.
Ticker impact
Relmada Therapeutics appointed Jørn Skibsted Jakobsen as Chief Development Officer, Urology & Uro-Oncology, to lead NDV-01 Phase 3 development.
potential slight upside as investors price in stronger development capability
New CDO brings proven uro‑oncology experience; no immediate financial impact but could de‑risk the upcoming Phase 3 trial.
Market effects
May boost sentiment in the biotech uro‑oncology niche, but limited broader sector impact.
U.S. biotech market sees a minor positive cue.
Minimal global effect beyond Relmada.
Counterpoint
Executive hires rarely move small‑cap biotech stocks; the appointment may be priced in already.
Key entities
- CompanyRelmada Therapeutics, Inc.
Clinical‑stage biotech developing NDV-01 and sepranolone.
- ExecutiveJørn Skibsted Jakobsen, MD, PhD
New Chief Development Officer, Urology & Uro‑Oncology.



